[1]
|
Nasef, N.A. and Mehta, S. (2020) Role of Inflammation in Pathophysiology of Colonic Disease: An Update. Interna-tional Journal of Molecular Sciences, 21, Article No. 4748. https://doi.org/10.3390/ijms21134748
|
[2]
|
Nakase, H., Uchino, M., Shinzaki, S., et al. (2021) Evidence-Based Clinical Practice Guidelines for Inflammatory Bowel Disease 2020. Journal of Gastroenterology, 56, 489-526. https://doi.org/10.1007/s00535-021-01784-1
|
[3]
|
Nikoopour, E., Bellemore, S.M. and Singh, B. (2015) IL-22, Cell Regeneration and Autoimmunity. Cytokine, 74, 35-42. https://doi.org/10.1016/j.cyto.2014.09.007
|
[4]
|
Keir, M., Yi, Y., Lu, T. and Ghilardi, N. (2020) The Role of IL-22 in Intestinal Health and Disease. Journal of Experimental Medicine, 217, e20192195. https://doi.org/10.1084/jem.20192195
|
[5]
|
Dumoutier, L., Louahed, J. and Renauld, J.C. (2000) Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9. The Journal of Immunology, 164, 1814-1819. https://doi.org/10.4049/jimmunol.164.4.1814
|
[6]
|
Ouyang, W.J. and O’Garra, A. (2019) IL-10 Family Cytokines IL-10 and IL-22: From Basic Science to Clinical Translation. Immunity, 50, 871-891. https://doi.org/10.1016/j.immuni.2019.03.020
|
[7]
|
Lopez, D.V. and Kongsbak-Wismann, M. (2022) Role of IL-22 in Homeostasis and Diseases of the Skin. APMIS, 130, 314-322. https://doi.org/10.1111/apm.13221
|
[8]
|
Zenewicz, L.A. (2018) IL-22: There Is a Gap in Our Knowledge. ImmunoHorizons, 2, 198-207.
https://doi.org/10.4049/immunohorizons.1800006
|
[9]
|
Eyerich, K., Dimartino, V. and Cavani, A. (2017) IL-17 and IL-22 in Immunity: Driving Protection and Pathology. European Journal of Immunology, 47, 607-614. https://doi.org/10.1002/eji.201646723
|
[10]
|
Zenewicz, L.A. (2021) IL-22 Binding Protein (IL-22BP) in the Regula-tion of IL-22 Biology. Frontiers in Immunology, 12, Article 766586. https://doi.org/10.3389/fimmu.2021.766586
|
[11]
|
Pavlidis, P., Tsakmaki, A., Pantazi, E., et al. (2022) Interleu-kin-22 Regulates Neutrophil Recruitment in Ulcerative Colitis and is Associated with Resistance to Ustekinumab Therapy. Nature Communications, 13, Article No. 5820.
https://doi.org/10.1038/s41467-022-33331-8
|
[12]
|
Li, L.-J., Gong, C., Zhao, M.-H. and Feng, B.-S. (2014) Role of Interleukin-22 in Inflammatory Bowel Disease. World Journal of Gastroenterology, 20, 18177-18188. https://doi.org/10.3748/wjg.v20.i48.18177
|
[13]
|
Zhao, Y., Liu, Z., Qin, L., Wang, T. and Bai, O. (2021) Insights into the Mechanisms of Th17 Differentiation and the Yin-Yang of Th17 Cells in Human Diseases. Molecular Immunol-ogy, 134, 109-117.
https://doi.org/10.1016/j.molimm.2021.03.010
|
[14]
|
Wu, B. and Wan, Y. (2020) Molecular Control of Pathogenic Th17 Cells in Autoimmune Diseases. International Immunopharmacology, 80, Article ID: 106187. https://doi.org/10.1016/j.intimp.2020.106187
|
[15]
|
Hou, Q., Ye, L., Liu, H., et al. (2018) Lactobacillus Accelerates ISCs Regeneration to Protect the Integrity of Intestinal Mucosa through Activation of STAT3 Signaling Pathway Induced by LPLs Secretion of IL-22. Cell Death & Differentiation, 25, 1657-1670. https://doi.org/10.1038/s41418-018-0070-2
|
[16]
|
Mizoguchi, A., Yano, A., Himuro, H., et al. (2018) Clinical Im-portance of IL-22 Cascade in IBD. Journal of Gastroenterology, 53, 465-474. https://doi.org/10.1007/s00535-017-1401-7
|
[17]
|
Nagao-Kitamoto, H., Leslie, J.L., Kitamoto, S., et al. (2020) Inter-leukin-22-Mediated Host Glycosylation Prevents Clostridioides difficile Infection by Modulating the Metabolic Activity of the Gut Microbiota. Nature Medicine, 26, 608-617. https://doi.org/10.1038/s41591-020-0764-0
|
[18]
|
Jin, M., Zhang, H., Wu, M., et al. (2022) Colonic Interleukin-22 Protects Intestinal Mucosal Barrier and Microbiota Abundance in Severe Acute Pancreatitis. The FASEB Journal, 36, e22174. https://doi.org/10.1096/fj.202101371R
|
[19]
|
Behnsen, J., Jellbauer, S., Wong, C.P., et al. (2014) The Cytokine IL-22 Promotes Pathogen Colonization by Suppressing Related Commensal Bacteria. Immunity, 40, 262-273. https://doi.org/10.1016/j.immuni.2014.01.003
|
[20]
|
Sakemi, R., Mitsuyama, K., Morita, M., et al. (2020) Altered Serum Profile of the Interleukin-22 System in Inflammatory Bowel Disease. Cytokine, 136, Article ID: 155264. https://doi.org/10.1016/j.cyto.2020.155264
|
[21]
|
Fu, S.-H., Chien, M.-W., Hsu, C.-Y., Liu, Y.-W. and Sytwu, H.-K. (2020) Interplay between Cytokine Circuitry and Transcriptional Regulation Shaping Helper T Cell Pathogenicity and Plasticity in Inflammatory Bowel Disease. International Journal of Molecular Sciences, 21, Article No. 3379. https://doi.org/10.3390/ijms21093379
|
[22]
|
Nakayama, T., Hirahara, K., Kimura, M.Y., et al. (2021) CD4+ T Cells in Inflammatory Diseases: Pathogenic T-Helper Cells and the CD69-Myl9 System. International Immunology, 33, 699-704. https://doi.org/10.1093/intimm/dxab053
|
[23]
|
Powell, N., Pantazi, E., Pavlidis, P., et al. (2020) Interleu-kin-22 Orchestrates a Pathological Endoplasmic Reticulum Stress Response Transcriptional Programme in Colonic Epi-thelial Cells. Gut, 69, 578-590.
https://doi.org/10.1136/gutjnl-2019-318483
|
[24]
|
Fang, L., Pang, Z., Shu, W., et al. (2018) Anti-TNF Therapy In-duces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients with Crohn’s Disease. Inflammatory Bowel Diseases, 24, 1733-1744.
https://doi.org/10.1093/ibd/izy126
|
[25]
|
Camilleri, M. (2021) Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA, 325, 865-877.
https://doi.org/10.1001/jama.2020.22532
|
[26]
|
Drago, L., Valentina, C. and Fabio, P. (2019) Gut Microbiota, Dysbiosis and Colon Lavage. Digestive and Liver Disease, 51, 1209-1213. https://doi.org/10.1016/j.dld.2019.06.012
|
[27]
|
Canakis, A., Haroon, M. and Weber, H.C. (2020) Irritable Bowel Syndrome and Gut Microbiota. Current Opinion in Endocrinology & Diabetes and Obesity, 27, 28-35. https://doi.org/10.1097/MED.0000000000000523
|
[28]
|
Leung, J.M. and Loke, P. (2013) A Role for IL-22 in the Relationship between Intestinal Helminths, Gut Microbiota and Mucosal Immunity. International Journal for Parasitol-ogy, 43, 253-257.
https://doi.org/10.1016/j.ijpara.2012.10.015
|
[29]
|
Meynier, M., Baudu, E., Rolhion, N., et al. (2022) AhR/IL-22 Pathway as New Target for the Treatment of Post-Infectious Irritable Bowel Syndrome Symptoms. Gut Microbes, 14, Article 2022997.
https://doi.org/10.1080/19490976.2021.2022997
|
[30]
|
Yu, Z.-Q., Wang, W.-F., Dai, Y.-C., Chen, X.-C. and Chen, J.-Y. (2019) Interleukin-22 Receptor 1 Is Expressed in Multinucleated Giant Cells: A Study on Intestinal Tuberculosis and Crohn’s Disease. World Journal of Gastroenterology, 25, 2473-2488. https://doi.org/10.3748/wjg.v25.i20.2473
|
[31]
|
Wei, H.-X., Wang, B. and Li, B. (2020) IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology. Frontiers in Immunology, 11, Article 1315. https://doi.org/10.3389/fimmu.2020.01315
|
[32]
|
Wilson, M.S., Feng, C.G., Barber, D.L., et al. (2010) Redundant and Pathogenic Roles for IL-22 in Mycobacterial, Protozoan, and Helminth Infections. The Journal of Immunology, 184, 4378-4390.
https://doi.org/10.4049/jimmunol.0903416
|
[33]
|
Ronacher, K., Sinha, R. and Cestari, M. (2018) IL-22: An Under-estimated Player in Natural Resistance to Tuberculosis? Frontiers in Immunology, 9, Article 2209. https://doi.org/10.3389/fimmu.2018.02209
|
[34]
|
Dhiman, R., Indramohan, M., Barnes, P.F., et al. (2009) IL-22 Produced by Human NK Cells Inhibits Growth of Mycobacterium tuberculosis by Enhancing Phagolysosomal Fusion. The Journal of Immunology, 183, 6639-6645.
https://doi.org/10.4049/jimmunol.0902587
|
[35]
|
Dhiman, R., Venkatasubramanian, S., Paidipally, P., et al. (2014) Interleukin 22 Inhibits Intracellular Growth of Mycobacterium tuberculosis by Enhancing Calgranulin A Expression. The Journal of Infectious Diseases, 209, 578-587.
https://doi.org/10.1093/infdis/jit495
|
[36]
|
Benson, A.B., Venook, A.P., Al-Hawary, M.M., et al. (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Can-cer Network, 19, 329-359.
https://doi.org/10.6004/jnccn.2021.0012
|
[37]
|
Men, K., Huang, R., Zhang, X., et al. (2018) Delivery of Interleu-kin-22 Binding Protein (IL-22BP) Gene by Cationic Micelle for Colon Cancer Gene Therapy. RSC Advances, 8, 16537-16548. https://doi.org/10.1039/C8RA02580K
|
[38]
|
Hernandez, P., Gronke, K. and Diefenbach, A. (2018) A Catch-22: Interleukin-22 and Cancer. European Journal of Immunology, 48, 15-31. https://doi.org/10.1002/eji.201747183
|
[39]
|
Markota, A., Endres, S. and Kobold, S. (2018) Targeting Interleukin-22 for Cancer Therapy. Human Vaccines & Immunotherapeutics, 14, 2012-2015. https://doi.org/10.1080/21645515.2018.1461300
|
[40]
|
Kirchberger, S., Royston, D.J., Boulard, O., et al. (2013) Innate Lymphoid Cells Sustain Colon Cancer through Production of Interleukin-22 in a Mouse Model. Journal of Ex-perimental Medicine, 210, 917-931.
https://doi.org/10.1084/jem.20122308
|
[41]
|
Gronke, K., Hernández, P.P., Zimmermann, J., et al. (2019) Interleu-kin-22 Protects Intestinal Stem Cells against Genotoxic Stress. Nature, 566, 249-253. https://doi.org/10.1038/s41586-019-0899-7
|
[42]
|
Jiang, R. and Sun, B. (2021) IL-22 Signaling in the Tumor Mi-croenvironment. In: Birbrair, A., Ed., Tumor Microenvironment. Advances in Experimental Medicine and Biology, Vol. 1290, Springer, Cham, 81-88.
https://doi.org/10.1007/978-3-030-55617-4_5
|